

Ship to: Patient Office Other

Date:

Needs by Date:

PATIENT INFORMATION

PRESCRIBER INFORMATION

Patient Name
 Address
 Address 2
 City, State, ZIP
 Preferred Phone Type
 Alternate Phone Type
 Email
 DOB (mm/dd/yyyy) Gender Male Female

Prescriber Name Specialty
 State License # UPIN
 DEA NPI
 Group/Hospital
 Address
 City, State, ZIP
 Phone Fax
 Office Contact Phone

INSURANCE INFORMATION (Please fax FRONT and BACK copy of all Insurance cards (Prescription and Medical))

CLINICAL INFORMATION

Diagnosis (Please include diagnosis name and ICD-10 code)
 Primary Diagnosis: Plaque Psoriasis Hidradenitis Suppurativa
 Atopic Dermatitis Other Diagnosis: _____
 ICD-10: _____
 Date of Diagnosis: _____
 Weight: _____ lbs/kgs Height: _____ in/cm
 Is the patient pregnant, nursing, or planning pregnancy?: Yes No N/A
 Date of last TB test (PPD or QuantiFERON Gold): _____
 Results: Positive Negative
 Allergies: _____
 Concomitant medications: _____

Therapy: New Continuing Therapy Restart
 BSA %:
 Affected Areas:
 Has the patient been previously treated for this condition? Yes No
 Prior failed medication (medication and duration of treatment/reason for d/c):
 Who will administer injection? (if applicable):
 Patient trained on injection? (if applicable): Yes No
 Pharmacy injection training needed? (if applicable): Yes No
 Additional comments:

PRESCRIPTION INFORMATION

| Medication | Dose/Strength | Directions | Qty | Refills |
|--|--|--|------------------|---------|
| <input type="radio"/> Cosentyx® (secukinumab) | <input type="radio"/> 150mg/ml prefilled syringe <input type="radio"/> 150mg/ml Sensoready Pen | <input type="radio"/> 300mg subcutaneously at week 0, 1, 2, 3, and 4 <input type="radio"/> 300mg subcutaneously every 4 weeks <input type="radio"/> Other: | 10 | 0 |
| <input type="radio"/> Dupixent® (secukinumab) | <input type="radio"/> 300mg/2ml prefilled syringe | <input type="radio"/> 600mg subcutaneously initially <input type="radio"/> 300mg subcutaneously every other week | 2 2 | 0 |
| <input type="radio"/> Enbrel® (etanercept) | <input type="radio"/> 25mg/0.5ml multi-dose vial <input type="radio"/> 25mg/0.5ml prefilled syringe <input type="radio"/> 50mg/ml prefilled syringe <input type="radio"/> 50mg/ml SureClick Pen <input type="radio"/> 50mg/ml Mini Cartridge | <input type="radio"/> 50mg twice weekly X 12 weeks, then once weekly <input type="radio"/> 50mg subcutaneously once weekly <input type="radio"/> _____ mg (0.8mg/kg x _____ kg) subcutaneously once weekly (peds ≤63kg) <input type="radio"/> Other: | | |
| <input type="radio"/> Humira® (adalimumab) | <input type="radio"/> 40mg/0.8ml prefilled syringe <input type="radio"/> 40mg/0.8ml pen | <input type="radio"/> 80mg subcutaneously on day 1, 40mg on day 8, then 40mg every 2 weeks (Psoriasis Starter Kit) <input type="radio"/> 160mg subcutaneously on day 1, 80mg on day 15, then 40mg weekly starting on day 29 (Hidradenitis Starter Kit) <input type="radio"/> 40mg subcutaneously every other week <input type="radio"/> 40mg subcutaneously once weekly <input type="radio"/> Other: | 4 6 | 0 0 |
| <input type="radio"/> Otezla® (apremilast) | <input type="radio"/> 10/20/30mg tablet starter <input type="radio"/> 30mg tablet | <input type="radio"/> Take as directed per package instructions <input type="radio"/> 30mg by mouth twice daily <input type="radio"/> Other: | 55 60 | 0 |
| <input type="radio"/> Siliq (brodalumab) | <input type="radio"/> 210mg/1.5ml prefilled syringe | <input type="radio"/> 210mg subcutaneously on week 0, 1, 2 <input type="radio"/> 210mg subcutaneously every 2 weeks | 3 | 0 |
| <input type="radio"/> Stelara® (ustekinumab) | <input type="radio"/> 45mg/0.5ml prefilled syringe (≤100kg) <input type="radio"/> 90mg/ml prefilled syringe | <input type="radio"/> 45mg subcutaneously initially and 4 weeks later <input type="radio"/> 45mg subcutaneously every 12 weeks <input type="radio"/> 90mg subcutaneously initially and 4 weeks later <input type="radio"/> 90mg subcutaneously every 12 weeks | 2 1 2 1 | 0 0 |
| <input type="radio"/> Taltz® (ixekizumab) | <input type="radio"/> 80mg/ml prefilled syringe <input type="radio"/> 80mg/ml autoinjector pen | <input type="radio"/> 160mg subcutaneously initially, then 80mg every 2 weeks for 3 months <input type="radio"/> 80mg subcutaneously every 4 weeks <input type="radio"/> Other: | 8 1 | 0 |
| <input type="radio"/> Tremfya™ (guselkumab) | <input type="radio"/> 100mg/1ml prefilled syringe | <input type="radio"/> 100mg subcutaneously on week 0, and week 4 <input type="radio"/> 100mg subcutaneously every 8 weeks | 2 1 | 0 |

By signing below, I authorize Lumicera Health Services and its representatives to act as my agent for prior authorization and prescription processing for this patient.

Prescriber Signature: _____

PRODUCT SUBSTITUTION PERMITTED

Date

DISPENSE AS WRITTEN